GV.PA €0.002 pre-market on EURONEXT, 38.49M vol: liquidity watch 13 Jan 2026
GV.PA stock opened pre-market at €0.002 on EURONEXT with heavy trading — 38.49M shares traded versus a 14.22M average. That surge makes Genomic Vision SA (GV.PA) one of today’s most active names in Europe, but liquidity and valuation remain challenges. Volume is driving short-term moves while fundamentals show a small market cap (€693,191.00) and negative EPS. We use Meyka AI’s data to connect trading flow to the company outlook and short-term forecast for active traders and value-focused investors.
GV.PA stock pre-market moves and volume snapshot
GV.PA stock is trading €0.002 pre-market on EURONEXT after opening at €0.002, up roughly 5.88% from the prior close, with a day range of €0.002 (high) and €0.002 (low) on heavy volume of 38.49M shares. Relative volume is 2.71x the average, which explains the large intraday swings and makes the name highly tradable but also susceptible to rapid price gaps.
Business model and competitive position in Medical Diagnostics
Genomic Vision SA (GV.PA) develops single-DNA detection tools and sells the FiberVision platform and consumables to research and diagnostics labs, operating from Bagneux, France. The company lists strategic partners such as Quest Diagnostics and research ties to Institut Pasteur, but with only 33 full-time employees it remains a niche player in Medical – Diagnostics & Research.
Key financials and valuation metrics for GV.PA
The company shows an EPS of -0.11 and a negative PE (approx -0.02), market cap €693,191.00, price-to-sales 0.47, and cash per share €0.0056. Short-term liquidity ratios are weak (current ratio 0.91) and free cash flow per share is negative €-0.0331, indicating continued funding risk despite low market capitalisation.
Technical, trading metrics and volatility signals
Current price sits below the 50-day average (€0.005) and 200-day average (€0.014), signaling a long-term downtrend. Average volume is 14.22M; today’s 38.49M shows episodic interest. Watch wide bid-ask spreads, low market cap, and large percentage moves — they create trading opportunities but also elevated execution risk for larger orders.
Meyka AI rates GV.PA with a score out of 100 and model forecast
Meyka AI rates GV.PA with a score out of 100: 58.75 | Grade: C+ | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst consensus. Meyka AI’s forecast model projects a 12‑month base-case price of €0.0045, implying 150.00% upside from the current €0.002, and a downside stress case near €0.0010 (approx -44.44%). Forecasts are model-based projections and not guarantees.
Risks, catalysts and sector context for GV.PA
Principal risks include low liquidity, negative earnings, and a high enterprise-value-to-sales ratio, while catalysts could be partnership rollouts or new diagnostic approvals. Sector activity at major instrument vendors and diagnostics companies can lift sentiment; see recent JP Morgan healthcare conference coverage for context source and source.
Final Thoughts
GV.PA stock is among the most active pre-market names on EURONEXT today, trading €0.002 on a volume spike to 38.49M shares. That makes short-term trading possible but raises execution and liquidity risk for position sizes beyond a few thousand euros. Financially, Genomic Vision shows negative EPS (-0.11), low cash per share (€0.0056), and a current ratio below 1, underscoring funding and operational challenges. Meyka AI’s model projects a 12‑month base-case target of €0.0045, implying 150.00% upside versus the present price, with a downside case near €0.0010 (approx -44.44%). Investors should weigh episodic volume and potential partnership catalysts against a weak balance sheet and persistent losses. For active traders, tight risk controls and small size are essential; long-term investors should require clear signs of revenue scale or capital strengthening. See more detail on the GV.PA company page at GV.PA on Meyka. Forecasts are model-based projections and not guarantees.
FAQs
What drives the recent GV.PA stock volume spike?
The spike reflects thin market cap and episodic orders: GV.PA trades €0.002 with relative volume 2.71x. Small trades can move price strongly; news, partnerships, or technical triggers typically amplify volume in micro‑caps.
How does Meyka AI rate GV.PA stock and what does it mean?
Meyka AI gives GV.PA a 58.75 score (Grade C+, HOLD). The grade compares sector and S&P benchmarks, financial growth, metrics and forecasts. It is informational, not investment advice.
What are realistic price targets for GV.PA stock?
Meyka AI’s model projects a 12‑month base-case €0.0045 (approx 150.00% upside) and a downside stress case near €0.0010 (approx -44.44%). These are model projections and not guarantees.
Should active traders consider GV.PA stock today?
Active traders may find intraday opportunity given 38.49M volume and high volatility, but should limit size and use strict stop losses due to low market cap, wide spreads and negative fundamentals.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
